| Verified against primary record | |
| Route one | Directive 2011/24/EU, reimbursement at home-state rates, Article 7(4)[1] |
|---|---|
| Route two | Regulation 883/2004, treatment under the treating state’s legislation, Article 20(2)[2] |
| Records read | Official Journal texts, 30 September 2026 |
| Independently reported | |
| Which route is better for the patient | Contested[5] |
| Bands apply only to the rows beneath them. The two routes are separate instruments, not variants of one scheme. No provider-supplied figures are used. | |
Government-funded treatment abroad is treatment in another country paid for by a public health system or social insurance scheme rather than by the patient. The phrase has no formal definition, but within the European Union two distinct legal routes exist, and they differ in ways that matter to a patient.
Two routes, not one
Under Directive 2011/24/EU the member state of affiliation must reimburse the costs of cross-border healthcare where the treatment is among the benefits to which the insured person is entitled at home.[1] Article 7(4) sets the rate: costs are reimbursed up to the level that would have been assumed had the healthcare been provided on the home state’s own territory, without exceeding the actual costs of the healthcare received.[1] Reimbursement may not be made subject to prior authorisation except in the cases set out in Article 8.[1]
Under Regulation (EC) No 883/2004 the mechanism is different. An insured person travelling to another member state to receive benefits in kind must seek authorisation from the competent institution, and an authorised person receives the benefits in kind provided on behalf of that institution by the institution of the place of stay, in accordance with the legislation that institution applies, as though the person were insured under it.[2] Authorisation must be accorded where the treatment is among the benefits provided at home and the person cannot be given it within a time limit which is medically justifiable, taking account of their current state of health and the probable course of the illness.[2]
The Directive itself acknowledges the overlap, providing in its recitals that for patients the two systems should be coherent, that either the Directive or the social security coordination rules apply, and that patients should not be deprived of the more beneficial rights guaranteed by those rules where the conditions are met.[1]
How the routes differ in practice
The Commission’s guidance for national contact points describes the practical consequence: under the Directive the patient will have to pay the costs of treatment upfront and is reimbursed according to the tariffs applied in the home country, whereas under the social security route prior authorisation on an S2 document is required before travelling and the patient is treated on the tariffs applied in the country of treatment, usually with third-party payment so that only the patient’s own share falls due.[3] The same guidance states that the patient is free to choose which of the two applies.[3]
National administration follows the same shape. The National Health Service describes a planned treatment route under which approval must be obtained before travelling, and states that where an application is approved the treatment will be provided under the same conditions of care and payment that apply to residents of the country of treatment, which could mean paying a percentage of the costs as a co-payment.[4]
Whether the social security route is always the better one for a patient is disputed. The Directive’s recitals presume it may confer more beneficial rights, while an analysis in the ERA Forum states that the assumption that the regulations are always the better option is not reliable.[5]
Related terms
Prior authorisation is the gate on both routes, though it operates differently on each. Treatment abroad scheme is the administrative name used in some national systems. No official figure separates patients using the Directive route from those using the social security route, because member states often cannot distinguish the two in their own returns.
See also
- Cross-border healthcare, the legal category both routes sit within
- Medical travel and waiting lists, the medically justifiable time limit that triggers authorisation
- Medical travel for rare diseases, where the Directive itself points to the social security route
- Insurer-arranged medical travel, the private analogue of prior authorisation
References
- European Parliament and Council. Directive 2011/24/EU of 9 March 2011 on the application of patients’ rights in cross-border healthcare, Articles 7(1), 7(4), 7(8) and recitals 30 and 31. OJ L 88/45, 4 April 2011. Verified against primary record: Official Journal text opened and read. Retrieved 30 September 2026.
- European Parliament and Council. Regulation (EC) No 883/2004 of 29 April 2004 on the coordination of social security systems, Article 20(1) and 20(2). Verified against primary record: text opened and read. Retrieved 30 September 2026.
- European Commission. Decision Tree for National Contact Points: Planned Cross-border Treatment. Publication date not stated. Independently reported: institutional guidance, not the legal text. Retrieved 30 September 2026.
- National Health Service. The Planned Treatment (S2 funding) route. Page last reviewed 16 January 2024. Independently reported: official administrative guidance. Retrieved 30 September 2026.
- Carrascosa Bermejo D. Cross-border healthcare in the EU: Interaction between Directive 2011/24/EU and the Regulations on social security coordination. ERA Forum, 15(3), pages 359 to 380, 2 October 2014. DOI 10.1007/s12027-014-0358-8. Independently reported: peer-reviewed legal analysis. Retrieved 30 September 2026.
Sourcing note: both EU instruments were opened in their Official Journal texts and the cited articles and recitals read on 30 September 2026. The Commission guidance, the national administrative page and the legal analysis are independently reported. The description of how the two routes differ in practice comes from Commission guidance rather than from the instruments, and the instruments are the authority where the two might differ. This entry describes the position within the European Union and makes no claim about publicly funded treatment abroad in other jurisdictions.